Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature

Autoimmunity Reviews

Volumn 13, Issue 10, 2014, Pages 1026-1034

  Ferri, Clodoveo ^a   Sebastiani, Marco ^a   Lo Monaco, Andrea ^b   Iudici, Michele ^c   Giuggioli, Dilia ^a   Furini, Federica ^b   Manfredi, Andreina ^a   Cuomo, Giovanna ^c   Spinella, Amelia ^a   Colaci, Michele ^a   Govoni, Marcello ^b   Valentini, Gabriele ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Autoantibodies; Lung fibrosis; Prognosis; Scleroderma; Skin ulcers; Survival

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; NUCLEOLAR ANTIBODY; SCL 70 ANTIBODY; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTHRITIS; CALCINOSIS; CLINICAL ASSESSMENT; DIAGNOSIS; DISEASE COURSE; DYSPHAGIA; DYSPNEA; FEMALE; HUMAN; HYPERPIGMENTATION; ITALY; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MIDDLE AGED; MYOSITIS; PATIENT REFERRAL; POPULATION; PREVALENCE; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; SJOEGREN SYNDROME; SKIN ULCER; SURVIVAL; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TELANGIECTASIA; BLOOD; CLINICAL TRIAL; EPIDEMIOLOGY; IMMUNOLOGY; LUNG; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SCLERODERMA, SYSTEMIC;

ANTIBODIES, ANTINUCLEAR; DISEASE PROGRESSION; FEMALE; HUMANS; ITALY; LUNG; MALE; PREVALENCE; PROGNOSIS; SCLERODERMA, SYSTEMIC; SURVIVAL RATE;

EID: 84908126065     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.029     Document Type: Review

References (74)

1. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
2. Medsger T.A. Systemic sclerosis (scleroderma): clinical aspect. A textbook of rheumatology 2005, vol. 2:1433-1465. Williams & Wilkins, Philadelphia. W.J. Koopman (Ed.).
3. Medsger T.A., Steen V.D. Classification and prognosis. Systemic sclerosis 2004, 51-64. Williams & Wilkins, Philadelphia. P.J. Clements, D.E. Furst (Eds.).
4. Ferri C., Bernini L., Cecchetti R., Latorraca A., Marotta G., Pasero G., et al. Cutaneous and serological subset of systemic sclerosis. J Rheumatol 1991, 18:1826-1832.
5. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002, 81:139-153.
6. Elhai M., Meune C., Avouac J., Kahan A., Allanore Y. Trends in mortality in patients with systemic sclerosis over 40years: a systematic review and meta-analysis of cohort studies. Rheumatology 2012, 51:1017-1026.
7. Ioannidis J.P.A., Vlachoyiannopoulos P.G., Haidich A.B., Medsger T.A., Lucas M., Michet C.J., et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005, 118:2-10.
8. Komócsi A., Vorobcsuk A., Faludi R., Pintér T., Lenkey Z., Költo G., et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology 2012, 51:1027-1036.
9. Krishnan E., Furst D.E. Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol 2005, 20:855-861.
10. Alamanos Y., Tsifetaki N., Voulgari P.V., Siozos C., Tsamandouraki K., Alexiou G.A., et al. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum 2005, 34:714-720.
11. Al-Dhaher F.F., Pope J.E., Ouimet J.M. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010, 39:269-277.
12. Altman R.D., Medsger T.A., Bloch D.A., Michel B.A. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991, 34:403-413.
13. Arias-Nuñez M.C., Llorca J., Vazquez-Rodriguez T.R., Gomez-Acebo I., Miranda-Filloy J.A., Martin J., et al. Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study 2008, 87:272-280.
14. Bryan C., Howard Y., Brennan P., Black C., Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996, 35:1122-1126.
15. Czirják L., Kumánovics G., Varjú C., Nagy Z., Pákozdi A., Szekanecz Z., et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008, 67:59-63.
16. Eason R.J., Tan P.L., Gow P.J. Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognosis feature. Aust N Z J Med 1981, 11:657-662.
17. Gelber A.C., Manno R.L., Shah A.A., Woods A., Le A.E., Boin F., et al. Race and association with disease manifestations and mortality in scleroderma. A 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine 2013, 92:191-205.
18. Giordano M., Valentini G., Migliaresi S., Picillo U., Vatti M. Different antibody patterns and different prognosis in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986, 13:911-916.
19. Hashimoto A., Tejima S., Tono T., Suzuki M., Tanaka S., Matsui T., et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 2011, 38:1931-1939.
20. Hesselstrand R., Scheja A., Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998, 57:682-686.
21. Hissaria P., Lester S., Hakendorf P., Woodman R., Patterson K., Hill C., et al. Survival in scleroderma: results from the population-based South Australian Register. Intern Med J 2011, 41:381-390.
22. Hoffmann-Vold A.M., Molberg Ø., Midtvedt Ø., Garen T., Gran J.T. Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol 2013, 40:1127-1133.
23. Jacobsen S., Halberg P., Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis. Br J Rheumatol 1998, 37:750-755.
24. Joven B.E., Almodovar R., Carmona L., Carreira P.E. Survival, causes of death, and risk factors associated with mortality in spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 2010, 39:285-293.
25. Kim J., Park S.K., Moon K.W., Lee E.Y., Lee Y.J., Song Y.W., et al. The prognostic factors of systemic sclerosis for survival among Koreans. Clin Rheumatol 2010, 29:297-302.
26. Laing T.J., Gillespie B.W., Toth M.B., Mayes M.D., Gallavan R.H., Burns C.J., et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997, 40:734-742.
27. Lee P., Langevitz P., Alderdice C.A., Aubrey M., Baer P.A., Baron M., et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992, 82:139-148.
28. Mayes M.D., Lacey J.V., Beebe-Dimmer J., Gillespie B.W., Cooper B., Laing T.J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003, 48:2246-2255.
29. Medsger T.A., Masi A.T., Rodnan G.P., Benedek T.G., Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971, 75:369-376.
30. Nagy Z., Czirjak L. Predictors of survival in 171 patients with systemic sclerosis. Clin Rheumatol 1997, 16:454-460.
31. Nishioka K., Katayama I., Kondo H., Shinkai H., Ueki H., Tamaki K., et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 1996, 23:677-682.
32. Perez-Bocanegra C., Solans-LaqueD R., Simeon-Aznar C.P., Campillo M., Fonollosa-Pla V., Vilardell-Tarres M. Age-related survival and clinical features in systemic sclerosis patients older or younger than 65 at diagnosis. Rheumatology 2010, 49:1112-1117.
33. Rowell N.R. The prognosis of systemic sclerosis. Br J Dermatol 1976, 95:57-60.
34. Sampaio-Barros P.D., Bortoluzzo A.B., Marangoni R.G., Rocha L.F., Del Rio A.P., Samara A.M., et al. Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients. J Rheumatol 2012, 39:1971-1978.
35. Scussel-Lonzetti L., Joyal F., Raynauld J.P., Roussin A., Rich E., Goulet J.R., et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002, 81:154-167.
36. Simeón C.P., Armadans L., Fonollosa V., Solans R., Selva A., Villar M., et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003, 42:71-75.
37. Simeon C.P., Armadans L., Fonollosa V., Vilardell M., Candell J., Tolosa C., et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997, 56:723-728.
38. Steen V., Domsic R.T., Lucas M., Fertig N., Medsger T.A. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012, 64:2986-2994.
39. Mehra S., Walker J., Patterson K., Fritzler M.J. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12:340-354.
40. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
41. Tuffanelli D.L., Winkelmann R.K. Systemic scleroderma. A clinical study of 727 cases. Arch Dermatol 1961, 84:359-371.
42. Wynn J., Fineberg N., Matzer L., Cortada X., Armstrong W., Dillon J.C., et al. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985, 110:123-127.
43. Barnett A.J., Miller M.H., Littlejohn G.O. A survival study of patients with diagnosed with scleroderma over 30years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988, 15:276-283.
44. Bauer P.R., Schiavo D.N., Osborn T.G., Levin D.L., St Sauver J., Hanson A.C., et al. Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study. Chest 2013, 144:571-577.
45. Bennett R., Bluestone R., Holt P.J., Bywaters E.G. Survival in scleroderma. Ann Rheum Dis 1971, 30:581-588.
46. Matucci-Cerinic M., Allanore Y., Czirják L., Tyndall A., Müller-Ladner U., Denton C., et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009, 68:1377-1380.
47. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
48. van den Hoogen F., Khanna D., Fransen J., Johnson S.R., Baron M., Tyndall A., et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013, 72:1747-1755.
49. Colaci M., Giuggioli D., Vacchi C., Lumetti F., Iachetta F., Marcheselli L., et al. Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based cancer registry and review of the literature. Autoimmun Rev 2014, 13:132-137.
50. Giuggioli D., Manfredi A., Colaci M., Manzini C.U., Antonelli A., Ferri C. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev 2013, 12:1058-1063.
51. Catoggio L.J., Bernstein R.M., Black C.M., Hughes G.R., Maddison P.J. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983, 42:23-27.
52. Heijnen I.A., Foocharoen C., Bannert B., Carreira P.E., Caporali R., Smith V., et al. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol 2013, 31:S96-S102.
53. Steen V.D., Powell D.L., Medsger T.A. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988, 31:196-203.
54. Altman D.G. Practical statistics for Medical Research 1991, Chapman et al, London.
55. Miller R.G. Survival analysis 1981, John Wiley, New York.
56. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc B 1972, 34:187-220.
57. Walker K.M., Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails - a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012, 42:42-55.
58. Poormoghim H., Moradi Lakeh M., Mohammadipour M., Sodagari F., Toofaninjed N. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int 2012, 32:2431-2444.
59. Marie I., Gehanno J.F., Bubenheim M., Duval-Modeste A.B., Joly P., Dominique S., et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014, 13:151-156.
60. Jimenez S.A., Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome. Autoimmun Rev 2013, 12:1046-1051.
61. Rossi D., Russo A., Manna E., Binello G., Baldovino S., Sciascia S., et al. The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev 2013, 12:821-825.
62. Frech T.M., Shanmugam V.K., Shah A.A., Assassi S., Gordon J.K., Hant F.N., et al. Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 2013, 31(Suppl. 76):166-171.
63. White B., Moore W.C., Wigley F.M., Xiao H.Q., Wise R.A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947-954.
64. Antic M., Distler J.H., Distler O. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?. Curr Opin Pharmacol 2013, 13:455-462.
65. Cipriani P., Carubbi F., Liakouli V., Marrelli A., Perricone C., Perricone R., et al. Stem cells in autoimmune diseases: implications for pathogenesis and future trends in therapy. Autoimmun Rev 2013, 12:709-716.
66. Fransen J., Popa-Diaconu D., Hesselstrand R., Carreira P., Valentini G., Beretta L., et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011, 70:1788-1792.
67. Hachulla E., Carpentier P., Gressin V., Diot E., Allanore Y., Sibilia J., et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology 2009, 48:304-308.
68. Tyndall A.J., Bannert B., Vonk M., Airò P., Cozzi F., Carreira P.E., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010, 69:1809-1815.
69. Gilbane A.J., Denton C.P., Holmes A.M. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther 2013, 15:215.
70. Elhai M., Avouac J., Kahan A., Allanore Y. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev 2013, 12:1052-1057.
71. Careta M.F., Leite Cda C., Cresta F., Albino J., Tsunami M., Romiti R. Prospective study to evaluate the clinical and radiological outcome of patients with scleroderma of the face. Autoimmun Rev 2013, 12:1064-1069.
72. Masi A.T. Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 1988, 15:894-898.
73. Koenig M., Dieudé M., Senécal J.L. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008, 7:588-593.
74. Vlachoyiannopoulos P.G. Clinical presentation and outcome of systemic sclerosis. Autoimmun Rev 2004, 3:S54-S55.